Nippon Shinyaku Co., Ltd. (4516) Press Release
Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation
Earlier from Nippon Shinyaku
- Nippon Shinyaku: and Elixirgen Enter into an Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
- Nippon Shinyaku: Orphan Drug Designation granted to NS-035 for the Treatment of Fukuyama congenital muscular dystrophy in Japan
- Nippon Shinyaku: Enters into a Sponsored Research Agreement with Boston Children’s Hospital
- Nippon Shinyaku: Outline of Consolidated Financial Results for the Year Ended March 31, 2026